New Insight: Exploring ENCELTO for MacTel with Rich Small, CEO of Neurotech
Welcome back to New Insight with Veeral Sheth, MD!
Veeral Sheth, MD, is joined by Rich Small, the CEO of Neurotech, to discuss the historic approval of revakinagene taroretcel (ENCELTO) a groundbreaking encapsulated cell therapy for macular telangiectasia type 2 (MacTel). This approval marked the first and only FDA–approved treatment for MacTel, a neurodegenerative disease of the retina that can cause progressive and irreversible vision loss.
Speaking with Sheth, Small recounted the long journey of Neurotech, which began in 2007, emphasizing the perseverance required to bring ENCELTO to…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.